<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) is associated with human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> such as nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp>, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, and gastric <z:mp ids='MP_0002038'>carcinoma</z:mp> (GC) </plain></SENT>
<SENT sid="1" pm="."><plain>EBV is associated with about 10% of <z:hpo ids='HP_0000001'>all</z:hpo> GC cases globally </plain></SENT>
<SENT sid="2" pm="."><plain>EBV-associated GC has distinct features from EBV-negative GC </plain></SENT>
<SENT sid="3" pm="."><plain>However, it is still unclear if <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> has any effect on GC chemoresistance </plain></SENT>
<SENT sid="4" pm="."><plain>Cell proliferation assay, cell cycle analysis, and active caspase Western blot revealed that the EBV-positive GC cell line (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>-EBV) showed chemoresistance to docetaxel compared to the EBV-negative GC cell line (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Docetaxel treatment increased expression of Bax similarly in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>-EBV cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>However, Bcl-2 induction was markedly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>-EBV cells, after docetaxel treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Although docetaxel increased the expression of p53 to a similar extent in both cell lines, induction of p21 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>-EBV cells was lower than in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, expression of survivin was higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>-EBV cells than in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> cells following docetaxel treatment as well as at basal state </plain></SENT>
<SENT sid="9" pm="."><plain>EBVlytic gene expression was induced by docetaxel treatment in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>-EBV cells </plain></SENT>
<SENT sid="10" pm="."><plain>The results suggest that <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> and lytic induction confers chemoresistance to GC, possibly by regulating cellular and EBV latent and lytic gene expression </plain></SENT>
</text></document>